Curated Wealth Partners 13F: Cuts ABT Stake by $398M

Curated Wealth Partners made a sharp move on its healthcare holdings, slashing its investment in Abbott Laboratories (NYSE: ABT) by a wide margin according to a Form 13F filing on October 15, 2026. Institutional filings like this look backward at the previous quarter's activity, meaning these trades took place earlier and might not reflect the fund's current stance today.

Inside Curated Wealth Partners's Abbott Laboratories Trade

During the filing period, Curated Wealth Partners trimmed its position by a steep 99.7%, shedding 4,024,218 shares. The fund was left holding just 13,175 shares of the medical device maker, with a reported value of about $1.3 million. That is a massive downgrade from its previous stake of 4,037,393 shares.

Other Institutional Activity in Abbott Laboratories

Other big players adjusted their holdings around the same time. Blackrock Inc. grew its holdings by 6,876,428 shares, ending with 152,563,476 shares worth about $16.0 billion. Vanguard Capital Management LLC grew its holdings by 801,938 shares, ending with 113,750,994 shares worth about $11.9 billion. State Street Corporation grew its holdings by 1,352,749 shares, ending with 80,926,234 shares worth about $8.5 billion. Charles Schwab Investment Management, Inc. grew its holdings by 14,173,548 shares, ending with 59,674,507 shares worth about $6.3 billion. Vanguard Portfolio Management LLC grew its holdings by 1,073,944 shares, ending with 49,017,866 shares worth about $5.1 billion.

Abbott Laboratories Stock Up 2.3%

Abbott Laboratories shares recently traded around $104.70 as of October 16, 2026. The stock sits about 1.2% below its 50-day moving average of $105.93 and roughly 1.7% above its 200-day moving average of $102.91. Shares are down about 20.7% from their 52-week high of $132.03 while staying 27.7% above their 52-week low of $81.97.

Recent Earnings

Abbott Laboratories posted trailing twelve-month revenue of $46.6 billion alongside basic earnings of $3.1 per share. The company reported a net profit margin of 11.6% and a return on equity of 10.6%. Its revenue grew at a 13.0% clip year-over-year. The company's next earnings report is scheduled for October 21, 2026.

Dividend

Abbott Laboratories pays an annual dividend yielding 2.41%, backed by a payout ratio of 78.7%.

Insider Buying and Selling at Abbott Laboratories

Company insiders were active in the stock over the months leading up to the filing. On May 7, 2026, Director John G. Stratton bought 2,000 shares at an average price of $86.82 for a total of $173,640. Later, on August 11, 2026, Officer Louis H Morrone sold 5,850 shares at $109.83 for $642,506. Chief Executive Officer Robert B. Ford sold 398,832 shares on August 25, 2026, worth about $46.2 million. Finally, on September 2, 2026, Officer John A. Mccoy Jr sold 27 shares at $109.54 for a total of $2,958.

Analysts Set New Price Targets

Wall Street analysts have generally favored the stock. On August 21, 2026, TD Cowen maintained its Buy rating and raised its price target to $135.00 from $115.00. TD Cowen repeated that Buy rating and $135.00 target on August 25, 2026, and again on September 8, 2026. Later, on October 2, 2026, Rothschild & Co upgraded the stock to Buy while lifting its target to $127.00 from $119.00. Barclays initiated coverage on October 7, 2026, with an Overweight rating and a $120.00 price target. Across 26 analyst opinions, the stock carries a consensus strong buy recommendation and a mean price target of $120.72.

About Abbott Laboratories

Abbott Laboratories is a global healthcare giant headquartered in Abbott Park, Illinois. The company discovers, develops, manufactures, and sells a wide variety of medical products. Its operations span established pharmaceuticals, diagnostic tools, nutritional goods, and advanced medical devices used by patients worldwide.

Bottom Line

Curated Wealth Partners's massive reduction leaves it with a tiny footprint in Abbott Laboratories. Investors should watch the company's upcoming earnings report on October 21, 2026, for fresh updates on financial health and market demand. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.